“…These results suggest that the antagonism observed for 2,2',4,4',5,5'-hexaCB may occur by mechanisms other than through the Ah receptor (Davis and Safe, 1990). A recent study by De Jongh et al (1995) has shown that the concentration of TCDD in the liver (% dose/ g tissue) was increased in the animals cotreated with TCDD and 2,2',4,4',5,5'-hexaCB compared to the animals treated with TCDD alone. The increase in the hepatic retention and subsequent decrease in available TCDD reaching the palate may contribute to the antagonistic action of 2,2',4,4',5,5'-hexaCB.…”